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              The methylation at the α-N-terminal amines of proteins that start with a 
canonical motif X-P-K (X=A/P/S) has been a known modification for nearly four decades. 
In 2010, protein α-N-terminal methyltransferase 1 (NTMT1/NRMT1) was identified as 
the first enzyme responsible for this modification. NTMT2 was discovered as a second 
member belonging to this family, but it was reported as a mono-methylase. The 
identification of RCC1, retinoblastoma (Rb) protein, centromere protein-A/B (CENP-A/B), 
and DNA damaged-binding protein 2 (DDB2) as new NTMT1 substrates revealed 




and damaged DNA repair, respectively. Although significant progress had been made, a 
clear understanding of how NTMT1 recognizes substrates remains to be determined. 
Also, there is no specific small molecule inhibitor for NTMT1.  
              To fill these gaps, we first established a fluorescence-based assay for kinetic 
characterization of NTMT1. Subsequently, ternary complex crystal structures of NTMT1 
were obtained to illustrate the structural basis for enzyme-substrate interactions. The 
structures of the enzyme-substrate complex coupled with mutagenesis, binding, and 
enzymatic studies demonstrated the key elements involved in interaction with its 
substrates. In the meantime, we utilized computational studies and fluorescence assays 
for novel small molecule discovery. Lastly, we closely monitored the substrates’ 
methylation progression by NTMT1 and NTMT2 in parallel using a MALDI-MS based 
assay.   
              Our results indicated that NTMT1 follows a Bi-Bi mechanism, and its 
methylation proceeds in a distributive pattern. Furthermore, NTMT1 was identified has 
broad substrate specificity beyond its canonical motif X-P-K (X=A/P/S), since X can be 
any amino acid except D/E and the third amino acids can also be R. We had also 
discovered an inhibitor that targets the substrate binding site of NTMT1 with IC50 = 7 µM. 
Lastly, our methylation progression studies has demonstrated that NTMT2 can also di-, 
tri-methylate certain substrates although its methylation rate is lower than NTMT1. 
              Overall, this project has laid the foundation for further investigation of N-







              Post translational modification (PTM) is a biochemical process utilized by 
nature to alter the “chemical makeup” of various proteins and molecules.1 In this 
process, substrates are covalently modified through “addition” or “removal” of different 
functional groups including acetylation, phosphorylation and methylation.2-4 PTM is 
believed to be “nature’s unique way to escape from genetic imprisonment.”2 So far, 
about 400 types of PTMs have been discovered, and more than 90,000 modifications 
have been identified. PTM has emerged as a major regulatory mechanism in different 
life forms through changes in subcellular localization, enzymatic activities, protein 
stability, and interactions with other proteins or molecules.1  
              PTMs are generally catalyzed by two types of enzymes. One type is referred 
as a “writer” such as the methyltransferases, acetyltransferases and kinases that add 
chemical groups to substrates. The other type is called an “eraser” such as the 
demethylase, deacetylase, and phosphatase that remove corresponding modifications 
from substrates.1, 3 Generally, each PTM on each specific residue may represent a 
specific functional modification. In addition, combination of different types of PTM on the 
same substrate, leads to a diversified mechanism to regulate protein structures and 
functions.3, 4 The histone code is a well-known example to illustrate such complexity of 
PTMs on its substrate, as the patterns of PTMs on the flexible histone tails regulate 





recognize specific PTMs serve as a third dimension of regulation to guide and 
determine the biological outcome of certain PTMs.5 
1.1 Acetylation  
              Acetylation refers to the covalent addition of an acetyl group to a protein.6, 7 
This modification was first identified on the epsilon amino group of a Lys residue of the 
histone protein in 1963.5 Therefore, the first identified enzyme responsible for 
acetylation is named histone acetyltransferase (HAT).8, 9 Recent studies discovered that 
acetylation can occur on many non-histone proteins such as tumor suppressor p53, 
transcriptional repressor protein YY1, high mobility group proteins, estrogen receptor α, 
hypoxia – inducible factor α and nuclear factor kappa-light-chain-enhancer of activated 
B cells.10-14 Hence, HATs have been renamed as lysine acetyltransferases (KATs) to 
reflect their ability to install an acetyl group on the side chain of a lysine residue of non-
histone proteins.5, 15 On the other hand, lysine deacetylases (KDACs/HDACs) can 
remove the acetyl group from the side chain of lysine.15 As interplays between KAT and 
KDAC regulate gene expression (Figure1), both KATs and KDACs are important 
epigenetic drug targets for various diseases including cancer, cardiovascular diseases, 







Figure 1. Protein acetylation and deacetylation. 
              Acetylation plays an important role in transcriptional activities, protein stability, 
and protein-protein interactions.7, 16 Acetylation on the epsilon amino group of the lysine 
residue under physiological conditions modifies the overall electrostatic properties of the 
protein.6, 9 Specifically, acetylation is one of the key epigenetic modifications that 
regulates chromatin structure because acetylated chromatin normally results in an open 








Figure 2. Acetylation and deacetylation of chromatin regulate gene expression.  
A. Acetylation (red sphere) on chromatins inhibits the folding of nucleosome arrays, 
which results in an open form to facilitate the access of transcription factors. B. 
Deacetylation of chromatins results in chromatin condensation, which in turn prohibits 
access of transcription factors.5 
               
 
1.2 Phosphorylation  
              Phosphorylation refers to the addition of a phosphate group that is provided by 
a co-factor called adenosine triphosphate (ATP) to serine, threonine, and tyrosine 
residues on its target molecules.19-25 Protein kinases are the enzymes responsible for 
phosphorylation modification.26-28 Based on the residue of phosphorylated, kinases are 
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Figure 3. Phosphorylation modification. 
              Phosphorylation is intensively involved in regulating protein conformation 
activities and signal transduction.19, 30 Under physiological conditions, the phosphoryl 
group is double negatively charged (Figure 3), and is frequently observed to have 
interactions with an Arg sidechain.19 This interaction is known to stabilize the 
conformational state of a protein. Enzymes can be activated through phosphorylation 
through allosteric conformational changes.19 One such example is glycogen 
phosphorylase, which exists in at least two functional states: the T (tense) state (a less 
active state), and the R (relaxed) state (a more actively state). The equilibrium between 
these two states is controlled by a phosphorylation switch.23 Phosphorylation can also 
inhibit enzyme activity through steric blockage of substrate recognition site using 
phosphate group.30 Additionally, in some cases, protein kinases may require 
phosphorylation at an allosteric site to induce a conformational change to create an 
active site for the subsequent phosphorylation.31  








              Methylation is a biochemical process of covalent addition of methyl groups to 
protein substrates.32-34 The history of methylation can be traced back to early 1960s with 
the discovery of N-methyl-lysine in the flagella protein of S. typhimurium. During an 
investigation of the origin of N-methyl-lysine residues in histone, N-dimethy-lysine was 
identified in 1967 and followed by the identification of N-trimethyl-lysine in 1968.32, 35, 36 
Those discoveries initiated the pursuit of the enzyme responsible for such methylation 
reactions.37 Interestingly, instead of discovering the protein responsible for lysine 
methylation, the first identified methylation protein was responsible for arginine 
methylation and is now known as protein arginine methyltransferse (PRMT).32 Since the 
introduction of modern biochemical techniques in 1995, many various types of 
methylation proteins have been discovered and their important biological functions have 
been revealed in signal transduction, gene regulation, biosynthesis, and protein repair.38, 
39 Because of its significance, methylation has drawn attention and has become a 
rapidly expanding field.32 
              Methyltransferase is the enzyme responsible for the methylation modification.33 
It catalyzes the transfer of a methyl group from the substrate S-adenosylmethionine 
(SAM) to its substrates, which range from small molecules to proteins. SAM’s primary 
role is donating a methyl group to different enzyme substrates. After the methyl group is 
transferred, SAM is converted to S-adenosylhomocysteine (SAH). So far, 
methyltransferases are thought to be the largest group of SAM-dependent enzymes 







Figure 4. Protein methylation catalyzed by methyltransferse.33 
 
1.3.1 Bisubstrate kinetic mechanisms  
              Protein methyltransferases belong to bisubstrate enzymes since they need to 
recognize both SAM and protein substrates. The kinetic mechanism of such bisubstrate 
enzyme is defined as the sequence of events in that its substrates are bound and 
products are released from the enzyme.40-42 A bisubstrate enzyme has two possible 
mechanisms: a sequential (bi-bi) mechanism or a Ping-Pong mechanism.40, 41, 43 As 
shown in Figure 5, in the sequential mechanism, both substrates “A” and “B” need to 
bind to the enzyme; “E” firstly to form a ternary complex “EAB” to trigger the catalytic 
activity of the enzyme. And both substrates will be converted into products “P” and “Q”, 











                                 Figure 5. Sequential (Bi-Bi) mechanism . 
 
 
              In the Ping-Pong mechanism, as shown in Figure 6, one of the substrate “A” 
needs to bind to the enzyme “E” to “covalently” modify it, and it will be released as 
product “P”. And this modified enzyme “F” will subsequently bind to another substrate “B” 
to modify it and release it as product “Q”. After modification of substrates, “F” converts 




                                        Figure 6. Ping-pong mechanism.  
 
              Understanding a kinetic mechanism is crucial for enzyme characterization, as 
well as inhibitor design. In order to determine the kinetic mechanism of a bisubstrate 
enzyme, one of the most common methodologies is the Lineweaver-Burk double 











                                   Figure 7. Lineweaver-Burk equation. 
              This equation is derived from Michaelis-Menten kinetics model as indicated in 
Figure 7. Based on this equation, by plotting a graph of reaction rate reciprocal (1/V) vs. 
substrate concentration reciprocal (1/[S]), a linear curve can be obtained with a slope of 
Km/Vmax and its intersect at 1/Vmax on y-axis. If an enzyme is adopting a sequential bi-bi 
mechanism, it should have an intersecting pattern as shown in Figure 8. Where, [A] and 
[B] represent corresponding substrate concentrations. Each curve represents different 




       Figure 8. Lineweaver-Burk plot of Bi-Bi and Ping-Pong mechanism.  
 
V: reaction rate 
V
max
: maximum enzyme reaction rate 
[S]: Substrate concentration 
K
m
: substrate concentration that contributes to half V
max
 





              In contrast, if the enzyme is adopting Ping-Pong mechanism, a parallel pattern 
should be observed from the Lineweaver-Burk plot. 40-42 
 
1.3.2 Protein arginine methyltransferases (PRMTs).               
              PRMTs methylate the guanidinium nitrogen of specific arginine residues on 
histones (Figure 9).44, 45 According to the types of methylated arginine products, PRMTs 
are divided into three subtypes. Type I PRMTs produce asymmetrically methylated di-
methylarginine. And type II PRMTs produce symmetrically methylated di-methylarginine. 
Type III PRMTs catalyze arginine mono-methylation.46 However, it is still unclear 
whether the mono-methylated product is the final product or an intermediate subject to 
further methylation.47 So far, eight PRMTs have been identified in humans: PRMT1, 
PRMT3, PRMT4, PRMT6, PRMT8 belong to type I. And PRMT5, PRMT7 belong to type 
II.46, 48 
              It is known that PRMTs are extensively involved in gene expression 
regulation.44, 49, 50 Among PRMTs, PRMT1 is involved in mRNA biosynthesis and 
heterochromatin formation. It also affects the subcellular localization of a number of its 
substrates.44 Another noticeable member in this family is PRMT5, which regulates cell 
cycle, transcription, differentiation, stem cells, spliceosome assembly, and so on. 







Figure 9. Protein arginine methylation. 
              Kinetic studies of PRMT1, PRMT5, and PRMT6 demonstrated that they all 
follow a Bi-Bi mechanism, which indicates the binding of both substrates to form a 
ternary complex.42, 43, 52 The gel-based activity methods were utilized in those studies, 
which utilizing 14C-labled SAM as the methyl donor. The incorporation of 14C-labled 
methyl group to the arginine residue of substrates is monitored by phosphorimager to 
determine the rate of methylation.42, 43, 52 
 
1.3.3 Protein lysine methyltransferases (PKMTs). 
              Site specific methylation of lysine on histone is regulated by a family of 
enzymes called PKMTs (Figure 10).53 This family possesses a highly conserved SET 
domain and is well-known as SET-domain protein methyltransferases.53-55 The SET 
domain is composed of approximately 130 residues; it was discovered as a conserved 
sequence in three Drosophila melanogaster proteins and was first characterized in 
1998.56, 57 So far, seven families of SET proteins are identified – SET 1, SET 2, SUV 39, 
EZ, RIZ, SMYD, and SUV4-20.
57, 58 In addition to those family members described above, 





              Although each PKMT has its specific roles, through methylating specific lysine 
with specific methylation states, PKMTs are extensively involved in epigenetic 
regulation of transcriptional activation, euchromatic/heterochromatic silencing, 
transcriptional elongation, and mitosis.60-65 However, their roles are not confined to 
histone methylation; SET 7/9 was reported to methylate K189 of TAFF10, which is a 
general transcriptional factor. Additionally, SET 7/9 was identified to be involved in 
methylation of tumor suppressor p53, to increase its stability. Aberrant histone 
methylation is linked to developmental disorders and diseases.59   












1.4 Protein α-N-terminal methylation. 
1.4.1 Discovery of α-N-terminal methylation 
              The first case of protein α-N-terminal methylation can be traced back to 1976 
during a study of ribosomal subunits from E. coli.66-69 It was identified that several 
ribosomal proteins; S11, L33 and L16, were methylated at their α-N-terminal amino 
groups.67 Before 1987, different groups reported cases of N-terminal methylated 
proteins of varied species.36, 70-72 Through sequence alignment of proteins that are 
subject to α-N-terminal methylation, several unique features of this modification were 
discovered. First, the first three amino acids at the N-termini of those proteins are 
relatively conserved, thus suggesting that they may serve as a recognition site for 
possibly enzymatic methylation. Second, the N-termini of prokaryotic and eukaryotic 
proteins possess different sequences. According to their methylation states and N-
terminal specificity, prokaryotic protein can be divided into two classes. One class is 
those proteins subject to mono-methylation, which is comprised of ribosomal protein 
L16, chemotaxis CheZ protein, ribosomal protein L33, and the translational initiation 
factor IF-3. Those proteins were further divided into two subclasses based on their N-
terminal sequences: L16 and CheZ possess glycine and proline at position 3 and 4, 
respectively. In contrast, IF-3 and L33 have either methionine or alanine at the N- 
terminus which is followed by lysine and glycine. In addition, there are two ribosomal 
protein subunits S11 and L11, they are also subject to N-terminal methylation. S11 has 
a unique N-terminal sequence of Ala-Lys-Ala. And L11 was the only identified 
prokaryotic protein that can be tri-methylated at that time, it has an N-terminal sequence 





Table 1. N-terminal sequence of prokaryotic proteins that are subject to N-terminal 
methylation.70 
 
Protein N-terminal sequence 
  L16 Met - Leu - Gln - Pro - 
CheZ Met - Met - Gln - Pro - 
  IF-3 Met - Lys - Gly - Gly - 
L33  Ala - Lys - Gly - IIe - 
  S11 Ala - Lys - Ala - Pro - 
L11 Ala - Lys - Lys - Val - 
 
 
              Compared to prokaryotic proteins that possess different N-terminal sequences 
and methylation states, all identified eukaryotic proteins that can be N-terminally 
methylated have a highly conserved N-terminal motif of Ala/Pro-Pro-Lys, and they all 
can be mono-, di-, tri-methylated.70 At that time, the identified proteins that possess this 
motif included myosin light chain LC-1, histone H2B, and cytochrome c-557. As most of 
these proteins are part of macromolecular complexes, it is believed that N-terminal 
methylation regulates protein-protein interaction. Since all of these proteins contain a 
Pro-Lys motif at the second and third position of their N-termini, it was hypothesized that 
a single enzyme named “PK methyltransferase” was able to recognize the unique N-
terminal motif to methylate those proteins. Unfortunately, due to the limited technologies 







 1.4.2 Discovery of protein N-terminal methyltransferase 1 & 2 (NTMT1/2) 
              In 2010 Webb et al. identified a protein named YBR261C/TAE1 that was 
responsible for N-terminal methylation of proteins through profiling of ribosomal proteins 
from yeast cells deficient in putative methyltransferases.73 YBR261C/TAE1 is conserved 
across eukaryotes; its deletion strain showed abolished N-terminal methylation 
capability. Along with the discovery of YBR261C/TAE1, two human homologues, 
METTL11a and METTL11b were also identified.73 Both YBR261C/TAE1 and METTL11a 
were demonstrated as active methyltransferases that recognize X-Pro-Lys N-terminal 
sequence, where X can be alanine, proline and serine. A further investigation of enzyme 
preference of the first residue of N-terminal sequence (X-Pro-Lys) suggests that those 
enzymes can recognize a variety of amino acids at the first position, and among which 
proline (Pro-Pro-Lys) had demonstrated the highest preference over other amino acids. 
Furthermore, through investigating the effects of substituting the second and third 
residues, it was found that both YBR261C/TAE1 and METTL11a prefer a Pro at position 
2, and a Lys at position 3.74 This result is in agreement with a previous study that all 
reported eukaryotic proteins subject to N-terminal methylation contain this motif.73 
              Interestingly, only three months after the first announcement of the 
identification of NTMT1 in 2010, Schanar-Tooley et al. had published the discovery of 
the first α-N-methyltransferase from Hela nuclear extracts and named it N-terminal 
RCC1 methyltransferase (NRMT).75 NRMT is essentially the same enzyme discovered 





ELISA as a methyltransferase responsible for RCC1 N-methylation. Multi-spindle 
formation was observed during mitosis through knockdown of NRMT.75 
              Through docking studies and mutagenesis, only a few residues in the peptide 
substrate binding site were suggested to be essential for enzyme catalytic activity. For 
example, mutation of either residue N169 or D181 to lysine had abolished enzyme 
activity. Additionally, through an N-terminal sequence search of GenBank, the SET 
oncogene and Rb protein were identified as new substrates of NRMT/NTMT1. Both 
proteins were later confirmed biologically as authentic substrates of NTMT1. As 
mentioned before, the Rb protein is also known as the tumour suppressor, it is a 
regulator of cell cycle, and identification of this protein for N-terminal methylation was of 
great importance.75-77 
              A homologue named METTL11b was identified along with discovery of 
NTMT1.73 However, a stable recombinant form of this protein was not obtained until 
2013. It was found that the second N-terminal methyltransferase named 
NRMT2/NTMT2 has a similar localization as its homologue NTMT1, and recognizes the 
same N-terminal motif of X-P-K. However, it was reported to be mainly a mono-
methylase as it only introduced one methyl group on its substrate.78 
 
1.4.3 NRMT/NTMT1 substrate specificity 
              Since the discovery of N-terminal methylation, it was believed that the second 





However in 2012, Petkowski et al. reported that the proline at the second position can 
be replaced by other residues: Ala, Glu, Met, Asn, Gln, Gly and Ser.79 
              In addition, Lys at position three had also been accepted as a highly conserved 
residue because replacing this lysine by glutamine was reported to result in diminished 
enzyme activity. Through testing the methylation of peptides with varied third residue, 
Petkowski et al. demonstrated that arginine can also fit into this position.79 This was 
further confirmed when centromere protein A (CNEP-A) was identified as a new 
substrate of NTMT1 in 2013.80, 81 It possesses a N-terminal sequence starting with Gly-
Pro-Arg.81-83 This study suggests that NTMT1 has broader substrate specificity than 
what was believed, and hence it was estimated that more than 300 proteins may be 
subject to N-terminal methylation based on this expanded substrate recognition.81 
 
1.4.4 Identification of new substrates of NTMT1. 
1.4.4.1 Regulator of chromatin condensation 1 (RCC1) 
              The knowledge of these N-terminal methylation modifications were largely 
uninvestigated until 2007, α-N-terminal methylation of a nucleotide - exchange factor 
named RCC1 was reported.84 RCC1 is the only known guanine nucleotide exchange 
factor for Ran GTPase, which plays indispensable roles in nucleo-cytoplasmic transport, 
nuclear envelope assembly, and spindle formation in cell mitosis.84-89 The association of 
RCC1 with chromatin through binding with histone H2A and/or H2B regulated by Ran is 






Figure 11. Diagram of RanGTP production.75  
              This is the first study that clearly demonstrated the function of N-terminal 
methylation and showed that methylated RCC1 N-terminus is essential for its 
association with chromatin, which in turn is crucial for cell mitosis. In order to examine 
the essentiality of RCC1 N-terminal methylation regarding its binding to chromatin, a 
series of RCC1 mutants were synthesized (APK-, PPK-, SPQ-, SPR-). Among them, 
mutant SPQ- showed abolished N-terminal methylation, and it was subsequently used 
for N-terminal methylation studies. Compared to wtRCC1, mutant RCC1 (SPQ-) with 
defected N-terminal methylation showed decreased binding efficacy to chromatin, which 
resulted in multi-spindle formation during mitosis. These results suggest the significance 
of RCC1 N-terminal methylation in cell mitosis.84 The discovery of the significance of 
RCC1 N-terminal methylation rebooted an interest in studies about protein N-terminal 







1.4.4.2 Centromere protein (CENP) 
              CENP is a chromatin region that serves as a spindle attachment point.80-82 It 
plays essential roles in chromosome segregation during cell division.90 CENP-B is a 
highly conserved centromere component that facilitates centromere formation in 
mammalian cells. It contains two important motifs: a DNA-binding motif at its N-terminus 
that binds specifically to a 17-bp DNA motif called CENP-B box within centromeric α-
satellite DNA, and a dimerization domain at its C-terminus.91, 92 
              The N-terminus of CENP-B, which is the DNA-binding motif, possesses a Gly-
Pro-Lys sequence.80, 93-95 Hence it had been reasoned that CENP-B might be a new 
substrate of NTMT1, which was confirmed in 2013 by Dai et al. that N-terminal 










              Meanwhile, CENP-A was also identified as a new substrate of NTMT1.95 
CENP-A is highly conserved among eukaryotes, and it is essential for the assembly of 
other centromeres. The function of N-terminal methylation of CENP-A remains elusive, 
but CENP-A contains a unique N-terminal motif of Gly-Pro-Arg.91, 95 It had been 
previously known that NTMT1 can recognize synthetic peptides that have different 
amino acids at the first position and the third residue can be an Arg. However, CENP-A 
and CENP-B are two natural substrates that possess Gly at the first position and Arg at 
the third position (CENP-A).91 Considering the significance and roles of those two 
proteins as histone variants in cell division, these discoveries again lit up the N-terminal 
methylation field. 
 
1.4.4.3 Discovery of damaged DNA-binding protein 2 (DDB2). 
              The UV-damaged DNA-binding protein complex (UV-DDB) is one of two 
principal initiators of the nucleotide-excision repair (NER) pathway, which is responsible 
for the repair of different type of DNA damages.96, 97 UV-DDB is a dimer complex 
composed of two subunits: a 127 kDa protein DDB1 and a 48 kDa protein DDB2, 
respectively. Through DDB2, UV-DDB binds specifically to the damaged site of DNA. 
Mutation of DDB2 was shown to cause cancer prone diseases such as xeroderma 







Figure 13. α-N-Terminal methylation of DDB2.98 
 
              DDB2 possesses an N-terminal motif of Ala-Pro-Lys, which suggested that 
DDB2 might also be a substrate of NTMT1 (Figure 13).98 In 2014, through a LC-MS/MS 
based assay, Cai et al. demonstrated that DDB2 is in fact a substrate of NTMT1, and 
was mostly tri-methylated during the experiment. Moreover, DDB2 mutants with 
defective N-terminal methylation had demonstrated diminished nuclear localization and 
reduced recruitment to damaged DNA foci, suggested an indispensable role for DDB2 
N-terminal methylation in UV-damaged DNA repair.98 
 
1.4.5 NTMT1 bisubstrate inhibitors 
              The biological significance of NTMT1 in cell mitosis, damaged DNA repair, and 
its upregulation in cancers has also motivated studies of NTMT1 inhibitor design. Kinetic 
mechanism studies of PRMTs and PKMTs had illustrated that many members from this 
family are adopting a sequential (Bi-Bi) mechanism, which requires the formation of a 
ternary complex to initiate enzyme activity.52 As a member of the methyltransferse family, 





synthesize a bisubstrate inhibitor by covalently linking a SAM analogue with a peptide 
substrate to mimic the ternary complex during enzyme catalysis. Such bisubstrate 
inhibitors could simultaneously inhibit both binding sites to provide potent and specific 
inhibitors.100 The bisubstrate inhibitor was designed by using N-adenosyl-L-methionine 
(NAM) to mimic SAM, which processes a more stable nitrogen instead of a active 
sulfonyl center. The N-terminal sequence derived from hRCC1 (SPKRIA) was used to 
mimic the peptide substrate of NTMT1. The NAM and SPKRIA are linked through a 
triazole linker based on our previous docking studies which shows that the sulfonyl 
group and α-amino group of the peptide is about 3.6 Å (Figure 14).101 
 
Figure 14. NTMT1 bisubstrate inhibitor.101 
              The designed bisubstrate inhibitor showed high inhibition potency (IC50 = 0.81 
+ 0.13 µM), which also demonstrating selectivity: our results indicate that it has less 
than 15% inhibition effect on PRMT1 and less than 50% inhibition effect on G9a. This 








1.5 Specific aims of this study  
              It has been forty years since the first identification of protein α-N-terminal 
modification. In the meantime, the enzyme that is responsible for this type of 
modification was identified as NRMT/NTMT1. Since discovery, its substrate specificity 
has expanded from X-P-K (X = S, P, A) to X-P-K/R (X = S, P, A, G). Beside the natural 
substrates, it was demonstrated that NTMT1 can also methylate different synthetic 
peptides, e.g., where X can be most natural amino acids. Also, the conserved second 
residue P can be replaced by other residues, although this observations somewhat 
controversial. 
              Along with those discoveries, several new substrates of NTMT1 were also 
identified. Among them, RCC1, Rb protein, oncoprotein SET, CENP-A/B and DDB2, 
enhanced the significance of N-terminal methylation. Those substrates play critical roles 
in chromatin segregation, cell cycle regulation, centromere formation, and UV-damaged 
DNA repair, respectively.  
              However, studies of N-terminal methylation are still in an early stage. So far, 
most studies about this modification have been focusing on its substrates’ function and 
substrate specificity. In order to understand N-terminal modification in a better 
perspective, it is important to obtain a comprehensive insight into the enzyme kinetics, 
substrate specificity, mechanisms, and inhibition of NTMT1. Hence, the specific aims of 
my graduate research are: 
1. To develop biochemical assays to understand the kinetic mechanism of NTMT1. 





3. To elucidate the molecular basis of substrate recognition in a combination of crystal 
structures, site-directed mutagenesis, biochemical assays and binding studies to 
characterize the contribution of residues regarding substrate recognition.  
4. To apply a combination of computational studies and biochemical assays to discover 
small molecule inhibitors for NTMT1. 
5. To understand the product specificity of NTMT1/2 through MALDI-MS base 
















2. Results and Discussion 
2.1 Fluorescence assay development 
2.1.1 Design  
              First, we need to establish a convenient and sensitive method to quantify 
methylation in order to characterize the kinetic mechanism of NTMT1. We adapted a 
fluorescence-based SAH hydrolase (SAHH)-coupled assay (Scheme 1), which monitors 
the conversion of SAM to SAH, using SAHH to catalyze the quantitative hydrolysis of 
SAH to adenosine and homocysteine (Hcy). Subsequently, the free thiol group of Hcy 
reacts with a sulfhydryl-sensitive fluorophore called ThioGlo1 to form an Hcy-Thioglo1 
adduct. This adduct has a strong fluorescence at 500 nm when it is excited at 370 nm. 
The concentration of Hcy is subsequently determined by fluorescent intensity. In 
essence, the rate of SAH production is measured during enzyme catalysis reactions in 
this assay.  
 RCC1-12 peptide (SPKRIAKRRSPP) derived from the N-terminus of RCC1 and 
showed exothermic binding to NTMT1 with a Kd = 70 µM, was used this RCC1-12 as 
the NTMT1 substrate in the fluorescence-based assay. It was synthesized using 
standard Fmoc chemistry on an automated peptide synthesizer and purified by reverse 






        Scheme 1. Schematic diagram of fluorescence-based assay mechanism. 
 
 













2.1.2 Assay optimization and validation 
The correlation study between fluorescence intensity and free thiol concentration  
 
 
Figure 15. Standard curve of fluorescence intensity vs. [GSH]. 
 
              Since the fluorescence intensity is our readout of the assay, the first thing was 
to ensure measured fluorescence intensity is proportional to product concentration. We 
used the commercially available glutathione (GSH) that contains a free thiol group to 
titrate the fluorescence intensity. The concentration range of GSH from 0 to 3 μM was 
examined in this study. We used excess amount of ThioGlo1 (15 μM) to ensure that 
ThioGlo1 is not a limiting factor. A standard curve of fluorescence intensity vs. GSH 
concentration was plotted in Microsoft Excel (Figure 15) and our results indicated that 







Comparison of fluorescent dyes 
              To investigate the sensitivity of the fluorescent dye, we compared two 
commonly used fluorophores: ThioGlo1 and CPM. Both dyes are specific to free thiol 
groups. The difference is that CPM-thiol adduct generates a strong fluorescence at 480 
nm. Under a similar condition as described above, we found the formations of thiol 
adduct with both ThioGlo1 and CPM is linear with respect to the GSH concentration. As 
shown in Figure 16, ThioGlo1 is more sensitive to free thiol with a larger slope. 
Therefore, we chose ThioGlo1 for the following studies. 
 









             For this study, NTMT1 (0.2 µM) was incubated in the reaction buffer containing 
25 mM Tris, 50 mM KCl, pH 7.5, 15 µM ThioGlo1, 10 µM SAHH, 100 µM SAM, and 100 
µM RCC1-12 at 37 °C. The concentration of formed product SAH during the reaction 
was derived from a standard calibration curve generated with glutathione and ThioGlo1. 
The result of this study indicated a linear relationship between product formation and 
reaction time during 12 minutes (R2 = 0.9919) (Figure 17). 10 µM SAHH was used to 
ensure that the hydrolysis of SAH was not rate-limiting as compared to NTMT1 catalysis.   
 












Concentration dependent studies 
 
 
                              Figure 18. Concentration dependent studies.41 
 
              In order to determine enzyme concentration and activity linearity range, 
concentration-dependent studies were conducted in the reaction buffer containing 25 
mM Tris buffer, 50 mM KCl, pH 7.5, 15 µM ThioGlo1, 10 µM SAHH, 100 µM SAM, and 
100 µM RCC1-12 at 37 °C. Initial velocity was analyzed using a time frame within 10% 
turnover using Microsoft Excel. Our result showed that the NTMT1 concentration is in 
linear relationships with reaction rates ranging from 0 to 0.4 μM (R2 = 0.9996. This result 
suggests that any enzyme concentration within this range should follow an enzyme 
concentration-activity linearity relationship. It was decided to use 0.2 μM as the assay 
concentration for NTMT1 kinetic studies, since it gave a better signal to background 







Km determination of SAM and RCC1-12 
 
 
Figure 19. Km Studies of SAM and peptide substrate RCC1-12.
41 
              The steady state kinetic parameters were determined for both RCC1-12 and 
SAM using our continuous fluorescence assay. As Km values of SAM for most protein 
methyltransferases are around 10 µM, we used 100 µM SAM that was assumed to be at 
a saturated concentration to determine the Km value of RCC1-12. Various 
concentrations (0-40 µM) of RCC1-12 peptide were incubated with the reaction mixture 
and fluorescence was monitored for 12 min. The Km of RCC1-12 was determined as 4.9 
+ 0.7 μM. Likewise, we used 50 µM of RCC1-12 peptide in the presence of various 









2.2 Bisubstrate kinetic mechanism characterization 
2.2.1 Design 
              The data for the initial rates of RCC1-10 peptide were determined at different 
fixed concentrations of the SAM (12.5, 25, 50, 100 µM). For reactions where the SAM 
was the varied substrate, the initial rates were examined at fixed concentration of 
RCC1-10 peptide (1, 2, 4, and 8 µM). The initial rates were globally fit to the following 




When A is saturating, αKB = Km
B  
  
KA and KB are the dissociation constants of the substrate A and B bind to the free 
enzyme, respectively. Vmax and Km are the Michaelis constants.
41 
 
2.2.2 Lineweaver-Burk double reciprocal plots 







)  K(RCC1) (µM) Km(RCC1) (µM) K(SAM) (µM) Km(SAM) (µM) 
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2.3±0.4 7.85±2.93 6.1±1.7 
a






              Km(RCC1-10), Km(SAM), K(RCC1-10) values were obtained when the concentration of 
RCC1-10 peptide was varied at different fixed concentrations of the SAM. Similarly, 
Km(RCC1-10), Km(SAM), and K(SAM) values were obtained when the concentration of SAM 
was varied at different fixed concentrations of the RCC1-10 (Table 2). The resulting 
double reciprocal plots exhibit an increasing slope with decreasing SAM and RCC1-10 
concentrations respectively, producing intersecting lines with the intercept lying in the 
second quadrant (Figure 20).41 This pattern indicates that NTMT1 catalysis proceeds in 
a sequential bi-bi mechanism. Therefore, NTMT1 requires formation of a ternary 
complex for the initiation of catalytic reaction, which further confirms our rationale of 
design for bisubstrate inhibitors. 
 
    Figure 20. Lineweaver-Burk plot of 1/v vs. 1/[RCC1-10] and 1/v vs. 1/[SAM].41  
 








2.3 NTMT1 methylation progression studies 
2.3.1 Design 
              As discussed previously, substrates of NTMT1 have different methylation 
states (mono-, di-, and tri-), but it was unknown how di-, or tri-methylation were 
achieved. If substrates are methylated from the unmethylated state to tri-methylated 
state in a single step, the methylation progression is following a “processive” 
mechanism. If substrates were methylated stepwise and intermediates were released 
during the enzyme catalysis, it is following a “distributive” fashion (Figure 21).  
               
 
 








2.3.2 Methylation progression studies via MALDI-MS 
            In order to unveil the methylation progression pattern of NTMT1, Dr. Stacie 
Richardson from our lab has developed a direct ratiometric quantification, matrix-
assisted laser desorption/ionization (MALDI)-MS assay to directly measure substrate 
concentrations of the varied methylation states.41 Following this method, Dr. Richardson 
monitored concentration of different intermediates at different time points (Figure 22). 
The total concentration of RCC1 used in this experiment was 10 μM. By utilizing the 
concentration of the RCC1 as an internal standard, and comparing the relative 
monoisotopic peak areas, we were able to measure the populations of all methylation 
states simultaneously.  
Methylation progression profiles indicate that both Me-RCC1 and Me2-RCC1 had 
reached 50% of the total substrate population.41 Thus, 5~6 μM of Me-RCC1 and Me2-
RCC1 were detected at different time points during the methylation progression. Since 
only 0.2 μM of NTMT1 was used in this assay, 5~6 μM of intermediates suggested that 
intermediates released from NTMT1 are accumulating in the reaction mixture, and 
subsequently rebound to NTMT1 for further methylation. Overall, the result of 
methylation progression assay suggests that NTMT1 follows a distributive methylation 
mechanism. However, a full-length protein substrate may exhibit a processive 
mechanism if it has significantly higher affinity to the enzyme or a slower off-rate than 
the enzyme turn-over time. Future study with full-length protein substrates would be 



















2.4 Effects of peptides’ length, methylation states, and sequences on substrate 
binding and recognition 
2.4.1 Design 
              NTMT1 is known to methylate proteins that contain an X-Pro-Lys motif.70 So far, 
peptides substrates used for NTMT1 kinetic studies were derived from the first twelve or 
ten residues of N-terminus of RCC1 since these were reported to have a binding affinity 
of 10 μM for NTMT1.79 However, contributions of length, methylation states, and key 
residues of NTMT1 substrates are still elusive. In order to understand the effects of 
peptide length regarding enzyme kinetics, we synthesized peptides of varied length 
(RCC1-6, RCC1-9, RCC1-10 and RCC1-12).  
    On the other hand, our methylation progression studies suggested that the 
mechanism of NTMT1 methylation is distributive.41 It is worth noting that upon each step 
of methylation, the N-terminus of substrate is sterically changed. So, we prepared 
peptides with varied methylation states to explore how methylation would affect 
substrate binding and recognition. To address this question, peptides of varied 
methylation state were synthesized: RCC1-10, MeRCC1-10, and Me2RCC1-10. Kinetic 
studies were carried out on these to determine the kinetic parameters of each peptide. 
              In order to investigate the contribution and define the specificity of the first 
residue of the recognition motif (X-Pro-Lys), we chose positively charged Arg, 
negatively charged Asp, polar aromatic Tyr, and the nonpolar hydrophobic residues Trp 





the Km, kcat, and kcat/Km values of each peptide. ITC analysis was utilized by our 
collaborator (Dr. Min’s lab) to directly analyze their binding affinities.  
               The second residue Pro at the N-terminus is highly conserved. To understand 
contributions of Pro regarding substrate binding and recognition, Dr. Min’s lab has 
designed peptides of varied second residues including I, Q, E, and S. 
 
2.4.2 Peptide length effect 
 Table 3. Kinetic studies of peptide substrates of varied length.41 
 
 
              The results of peptides’ length studies are summarized in Table 3. Kinetic 
studies on peptides with different lengths (6-12 mer) gave Km values from 0.81 to 4.72 
µM and kcat values from 0.43 to 0.61 min
-1. The kcat/Km values ranged from 1.78×10
5 to 
4.93×105 M-1 min-1. Among these four peptides, RCC1-10 has the lowest Km of 0.89 + 
0.09 μM, which suggests that a C-terminal residue to the Ser-Pro-Lys motif also 
contributes to substrate recognition. In comparison, all peptides of different lengths 
exhibited similar kcats, which suggests NTMT1 can efficiently catalyze a hexapeptide. 
 
Peptide ID Sequence K m (μM) k cat (min
-1





RCC1-6 SPKRIA 3.2 + 0.4 0.56 + 0.02 1.8 x 10
5
RCC1-9 SPKRIAKRR 1.4 + 0.1 0.53 + 0.01 3.8 x 10
5
RCC1-10 SPKRIAKRRS 0.89 + 0.09 0.44 + 0.01 4.9 x 10
5






2.4.3 Methylation state effect 
Table 4. Kinetic studies of peptide substrates of varied methylation state.41 
 
 
              Since RCC1-10 exhibited the lowest Km (Table 3), this peptide was chosen for 
the studies of methylation effects (Table 4). RCC1-10, MeRCC1-10, and Me2RCC1-10 
represent three different methylation states. The kinetic studies indicated that 
unmethylated (RCC1-10) and mono-methylated (MeRCC1-10) peptides have 
comparable Kms of 0.89 μM and 1.4 μM, respectively. In contrast, di-methylated peptide 
has a four-fold increased Km compared to the unmethylated peptide, which suggests 
that NTMT1 can bind and catalyze unmethylated and mono-methylated RCC1-10 in a 
similar fashion. But the di-methylated peptide may have introduced steric factors to an 
extent that affects substrate binding.  
              While comparing kcat of each peptides, it suggests that di-methylated RCC1-10 
has comparable turnover numbers compared to unmethylated and mono-methylated 
peptide, which further proved our hypothesis that varied methylation state can 
significantly affect substrate binding, yet NTMT1 can still efficiently catalyse peptides of 
different methylation state. 
 
Peptide ID Sequence K m (μM) k cat (min
-1





RCC1-10 SPKRIAKRRS 0.89 + 0.09 0.44 + 0.01 4.9 x 10
5
MeRCC1-10 Me-SPKRIAKRRS 1.4 + 0.1 0.58 + 0.01 4.1 x 10
5






2.4.4 Effects of the first residue 
              As the hexapeptide was shown to be efficiently methylated by NTMT1 in our 
previous study, our collaborator (Dr. Min’s lab) prepared a series of hexapeptides to 
investigate the contribution and the tolerability of the first residue of the N-terminus: 
SPKRIA (hRCC1), PPKRIA (mRCC1), RPKRIA (positively charged), YPKRIA (polar 
aromatic), WPKRIA (non-polar hydrophobic), LPKRIA (non-polar hydrophobic), and 









































Table 5. Steady state kinetic studies of peptides with varied first residue.102 
(ND) No detectable activity at 250 μM peptide and a saturating amount of SAM. 
 
               Steady state kinetic profiles of each peptides substrate are presented in 
Figure 23. Results of kinetic studies of these peptides with different first residues are 
summarized in Table 5. As indicated, despite the fact that the only structural variation of 
these peptides is the sidechain of the first residue, their Km values span from 0.3 µM 
(PPKRIA) to 126 µM (WPKRIA). Compared to SPKRIA (Km = 7.9 + 0.7 μM), both 
RPKRIA and YPKRIA have 2 ~ 4 fold lower Kms of 4.0 + 0.5 μM and 1.6 + 0.3 μM, 
respectively. This is in agreement with previous reported studies that the first residue 
can be positively charged due to the extensively negatively charged substrate binding 
site (see Appendix).79 A positively charged residue like arginine is electronically 





sidechain of the first residue, the size of which can accommodate an aromatic ring such 
as tyrosine.102 
              In comparison, the non-polar hydrophobic peptides WPKRIA and LPKRIA have 
significantly increased Kms of 126 + 7 μM and 54 + 6 μM, respectively, which suggests 
that the substrate binding site of the first residue is unfavorable with respect to non-
polar hydrophobic residues. Lastly, the negatively charged peptide DPKRIA did not 
show any sign of methylation; this is in agreement with a previous study that negatively 









































Figure 24. ITC analysis of peptides with varied first residues.102 
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Kd1 = 4.1 μM 
Kd2 = 0.1 μM 
PPKRIA 
Kd1 = 14 μM 
Kd2 = 0.8 μM 
Kd1 = 189 nM 






              Results of ITC analysis are in agreement with that of the kinetic studies. 
PPKRIA shows the best binding with Kd = 189 nM. RPKRIA (Kd = 3.7 uM) and YPKRIA 
(Kd = 4.1 µM) have about three folds lower Kd values compared to SPKRIA (Kd = 14 µM). 
Both hydrophobic residues WPKRIA (Kd = 47 µM) and LPKRIA (Kd = 48 µM) have 3-fold 
increased Kd compared to SPKRIA. Negatively charged DPKRIA did not show any sign 
of binding (Figure 24). 
              Interestingly, a bimodal binding was observed from the ITC profiles of some 
peptides (Figure 24).102 This is especially evident for those peptides with high binding 
affinities, such as PPKRIA, RPKTIA, and YPKRIA. We hypothesized that it may be 
attributed to the possibility that NTMT1 purified from E. coli contains endogenous SAM, 
which could consequently methylate peptides during ITC analysis. Co-purification of 
endogenous SAM along with methyltransferase has been documented before.103 
Therefore, the observed bimodal binding is resulted from a mixture of methylated and 
unmethylated substrates with their varied binding affinities for NTMT1. In order to test 
our hypothesis, the MALDI-MS based assay was carried out without external addition of 
SAM. As mentioned before, N-terminal methylation of a substrate requires the formation 
of a ternary complex of NTMT1–peptide–SAM. If NTMT1 used in the experiment does 













Figure 25. MALDI-MS spectra of S/P/Y/RPKRIA.102 
 
              Results of MALDI-MS based study are shown in Figure 25. Spectra that are 
named by peptide sequences are controls with peptides alone, from which only [M + H]+ 





plus NTMT1 contain [M + Me + H]+ peaks. Peptide with high binding affinity such as 
PPKRIA even contains the [M + 2Me]+ peak. The above results from MALDI–MS based 
assay supports our hypothesis that NTMT1 used in the experiment contains a certain 
amount of endogenous SAM, which causes the bimodal binding phenomenon observed 
from ITC analysis studies.102 
2.4.5 Effects of the second residue  
              Four peptides of varied second residues were synthesized: SIKRIA, SQKRIA, 
SEKRIA, SSKRIA. Kinetic studies were carried out to determine their kinetic parameters.   
Table 6. Steady state kinetic study results of peptides with varied second residues.102 
(ND) No detectable activity at 250 μM peptide and a saturating amount of SAM. 
 
              As summarized in Table 6, after replacement of the second Pro by IIe, Gln, Glu, 
and Ser, no methylation could be detected from fluorescence assay. Results from ITC 
analysis are consistent with results from kinetic studies, which are shown in Figure 26. 
Both kinetic studies and ITC analysis suggested that Pro2 is essential as the binding 
abilities of all four peptides are completely abolished. Previously reported substrate 
specificity studies of NTMT1 stated that the second residue Pro can be replaced by Ala, 
Glu, Met, Asn, Gln, Gly and Ser through in vitro peptide methylation assays and 

























Figure 26. ITC analysis of peptides with varied second residues.102 
 

























































































































































2.5 Structural basis study for substrate binding and recognition 
2.5.1 Design 
              New co-crystal structures of NTMT1 in complex with SAH and two different 
hexapeptide substrates including the human (hRCC1-6: SPKRIA) and mouse RCC1 
(mRCC1-6: PPKRIA) were successfully obtained by Dr. Jinrong Min’s lab at the 
Structural Genomics Consortium.102 These crystal structures reveal that its substrate 
peptides are inserted into a negatively charged channel of NTMT1 (see Appendix), 
which is in striking contrast to that of other protein methyltransferases (see Appendix). 
We identified a few key residues (N168, W136, D180 and D177) that contribute to the 
substrate recognition and performed site-directed mutagenesis studies to elucidate the 
interactions (Figure 27).102 
 
Figure 27. NTMT1–SAH–R/Y/SPKRIA ternary complex.102 
2.5.2 Kinetic studies of NTMT1 mutants 
              The carboxamide group of the side chain of Asn168 interacts with the 
backbone carbonyl group of Ser (Figure 27). To examine the contribution of Asn168, 





site-directed mutagenesis was carried out to replace Asn168 with a Lys. The results of 
kinetic studies that characterized through the fluorescence assay (Table 7) have 
demonstrated that N168K has ~36-fold higher of Km and two-fold lower of kcat than 
wtNTMT1.102 Therefore, this mutation has affected not only substrate binding and 
recognition, but also enzyme catalytic activity.  
              Trp136 was identified as having a stacking interaction with the sidechain of 
Pro2. After mutation of Trp136 to Phe, the kinetic parameters dramatically decreased 
with Km > 200 μM and kcat > 0.04 + 0.01 min
-1 (Table 7). Meanwhile, mutant of Trp136 to 
Ile has undetectable enzyme activity. Both mutants suggest the importance of the 
stacking interaction between side chains of Pro2 and Trp136.102 
Table 7. Steady state kinetic studies of NTMT1 mutants.102 
(ND) No detectable activity at 250 μM peptide and a saturating amount of SAM. 
              To examine the essentiality of the two interactions between Lys3 and 
Asp180/Asp177 (Figure 27), site directed mutagenesis was carried out to mutate both 
residues. Those mutations were expected to disrupt these electrostatic interactions. Our 
results from kinetic studies indicate that neither D180K nor D180Y have detectable 
methylation activity (Table 7). While integrating this result with the ITC analysis that 
Enzyme K m (μM) k cat (min
-1





Wide type 7.3 + 0.7 0.10 + 0.01 1.4 x 10
-2
N168K 263 + 141 0.05 + 0.01 1.9 x 10
-4
W136F >200 >0.04 + 0.01 /
W136I ND ND ND
D180K ND ND ND





performed by our collaborator, Dr. Min’s lab (Figure 28), it can be seen that the peptide 
substrate (SPKRIA) is not able to bind to either D180K or D180A, which further 
confirmed that the interaction between Asp180 and Lys3 is essential in terms of 
substrate binding. On the other hand, compared to wtNTMT1 (Kd =14 µM), D177A has 
about two-fold increased Kd (32 µM), which is an indication of the decreased binding 













Figure 28. ITC analysis of mutants D180A, D180K and D177A.102 


































Kd = 32 μM 


















































































































2.6 Discovery of a small molecule inhibitor for NTMT1 
2.6.1 Design              
               Specific chemical probes that modulate methylation have functioned as 
valuable chemical tools to investigate NTMT1-mediated biological processes. Our lab 
developed the first potent and specific NTMT1 bisubstrate inhibitor that displays an IC50 
of 0.8 µM for NTMT1 and is more than 60-fold selective over protein lysine 
methyltransferase G9a and arginine methyltransferase 1.101 The bisubstrate inhibitors 
offered us a valuable probe for biochemical studies of NTMT1, but have limited use in 
biological studies due to their low stability in the presence of serum in cell culture media. 
While we continue our efforts to optimize structures of our bisubstrate inhibitors, 
discovery of novel small molecule inhibitors for NTMT1 will be critical for the 
interrogation of the biological functions of NTMT1 and elucidatation of the different 
responses to knockdown of NTMT1 in normal and transformed cells.   
              We used the only available (at that time) X-ray crystal structure for the human 
NTMT1 protein in complex with product SAH (PDB ID: 2ex4, 1.75 Å) to predict the 
substrate binding site and develop the initial search query in collaboration with the Dr. 
Glen Kellogg’s lab. Our goal was to discover small molecule inhibitors that target the 
binding site of the peptide substrate; thus, the active site was defined by the cavity 




















2.6.2 Computational studies  
              We defined the query based on several features surrounding the pocket, 
including one aromatic site (Trp136), two acceptor sites (Asp177, Asp180), and one 
donor site (Asn168). The NTMT1 structure, including the SAH, was processed in Sybyl-
X 1.1 by deleting all water molecules, adding all protons and performing an energy 
minimization of these protons while holding the heavy atoms as an aggregate. Initial 
virtual screening was performed with the UNITY module of Sybyl against the open NCI 
database of 250,000 unique compounds. The resulting 150 UNITY hits were then 
docked with GOLD 5.1 and the highest scoring poses were then energy minimized and 
rescored with HINT. These 150 promising leads were ranked based on HINT score and 
were visually inspected. We requested from the NCI these high-ranking compounds for 













2.6.3 Biochemical screening with recombinant NTMT1 
Single dose inhibitory activity studies 
Figure 30. Results of 100 μM primary screening.  
 
              We aim to identify selective small molecule inhibitors that target the unique 
peptide substrate binding site of NTMT1, so we used an excess amount of SAM (100 
µM) and substrate peptide RCC1-12 peptide at its Km value of 5 µM in the screening. 
The reaction was allowed at 37 oC for 10 min with or without the addition of inhibitors. 
Obtained compounds were subject to single dose screening. 100 μM was used as the 
final inhibitor concentration. Results of single dose screening are shown in Figure 30. 





resulting top five compounds were chosen (NCI657593, NCI51367, NCI610742, 
NCI48774, and NCI73559) for subsequent studies. 
 
Secondary assays to remove false positives 
 
Figure 31. Secondary screening to remove false positive. 
              This experiment was conducted in order to exclude possibilities of false results. 
If an inhibitor is targeting SAHH, increasing SAHH concentration should show reduced 
inhibitory activity. Results from Figure 31 indicate that after doubled SAHH 
concentration, none of our compounds showed drastic changes in terms of inhibitory 
activity, and this suggests that their activity is not from SAHH inhibition.  
              Occasionally, introduction of a compound to the assay can result in protein 
aggregation. Aggregated enzymes normally have no enzymatic activity, which also 





assay to prevent protein aggregation. Through addition of triton, if the inhibitory activity 
of a compound is caused by aggregation, it would show reduced inhibitory activity. Our 
results indicate that NCI48774 showed significant reduced inhibitory activity after 0.04% 
of triton was added, which implies that this compound might introduce protein 
aggregation, and its inhibitory result is not reliable. 
IC50 studies 
          Table 8. IC50 studies. 
 
              IC50 is an important indicator of the potency of an inhibitor. In this study a three-
time serial dilution of each sample was carried out with DMSO. The inhibitory activities 
of compounds in different concentrations were monitored through fluorescence assay. 
The results of IC50 study indicate NCI657593 has the lowest IC50 of 7.4 + 0.6 µM. Other 







Table 9. Selectivity study. 
  
IC50 (µM) 
 Compound NTMT1 PRMT1 G9a 
NCI657593 7.4 + 0.6 µM >50 µM >50 µM 
 
              Inhibitor selectivity was determined by comparing IC50 values of the inhibitor 
with other methyltransferases; e.g. PRMT1 and G9a. As shown in Table 9, compared to 
NTMT1, compound NCI657593 has >50 µM IC50 for both arginine methyltransferases 
PRMT1 and lysine methyltransferase G9a, which suggests that it is selective for NTMT1 
among these three methyltransferases. 
Similarity search 






              Since NCI657593 showed extraordinary inhibitory activity, compounds that are 
structurally similar to NCI657593 were ordered. Subsequently, 100 µM single dose 
inhibition study and IC50 studies were conducted to examine their inhibitory activity. 
However, results indicate that all compounds possess >70 µM IC50 (Table 10). Even 
though NCI657593 was identified as a small molecule with significant inhibitory activity 
and selectivity, the molecular structure of NCI657593 remains to be validated through 

















2.7 Substrate specificity and methylation progression studies of NTMT1/NTMT2 
2.7.1 Project design 
              Along with the discovery of NTMT1 (METTL11A), a homologue named 
METTL11B (NTMT2) was also identified.81 NTMT2 recognizes the same N-terminal 
motif of X-P-K/R, and possesses N-terminal methylation activity.85 Structurally, NTMT2 
has about 50% sequence identity and 75% sequence similarity with NTMT1 (Figure 32). 
Those residues that were identified crucial for substrate binding and recognition in the 
substrate binding site (Trp136, Asn168, Asp177, Asp180) are also conserved in 
NTMT2.85 In addition, it has similar cellular localization and tissue expression pattern as 
NTMT1. However, as described previously, NTMT2 was reported as a monomethylase 
to prime the substrates of NTMT1 to facilitate further methylation of substrates by 
NTMT1. 
 





             The goal of this study is to analyze substrate and product specificity of NTMT1 
and NTMT2 to understand the role and function of NTMT2 and its relationship with 
NTMT1. Due to the low activity of NTMT2, we were not able to characterize the kinetic 
parameters through fluorescence assay. Hence we used a MALDI-MS based assay to 
monitor methylation progression for substrates of varied first residues with NTMT1 and 
NTMT2 in parallel. 
 
2.7.2 Methylation progression studies  
              Table 11. Methylation progression study results summary. 
 
 
              The results of these methylation progression studies of NTMT1 and NTMT2 
are summarized in Table 11. The remaining mass spectra of the other peptides are 
attached in Appendix (Figure 1 ~ Figure 26). As shown, both NTMT1 and NTMT2 can 
Peptide
Mono-methylation Di-methylation Tri-methylation




YPKRIA YES/YES YES/NO NO/NO
RPKRIA YES/YES YES/NO NO/NO
WPKRIA YES/YES YES/NO NO/NO
DPKRIA NO/NO NO/NO NO/NO
QPKRIA YES/YES YES/NO NO/NO
NPKRIA YES/YES YES/NO NO/NO
LPKRIA YES/YES YES/NO NO/NO
GPRRRS YES/YES YES/YES YES/YES






monomethylate most peptides except DPKRIA. From our previous studies, DPKRIA 
shows no binding to NTMT1, probably because the negatively charged aspartic acid is 
considered unfavorable for similarly negatively charged substrate binding site.  
              The difference between both enzymes starts to show at the di-methylation step. 
It indicates that, except peptides GPKRRQ and GPRRRS (and DPKRIA), all peptides 
can be di-methylated by NTMT1. However, none of them achieved di-methylation 
through NTMT2. It is also worth noting that from time-dependent methylation 
progression studies, NTMT2 showed an apparent slower methylation rate than NTMT1. 
Therefore, the di-methylation incapability of NTMT2 is whether due to its slower 
methylation rate, or another intrinsic mechanism remains to be discovered.  
              On the other hand, our results indicate that peptides with high binding affinity 
such as GPKRRQ, GPRRRS, and MePPKRIA had illustrated full methylation (tri-
methylation of GPKRRQ, GPRRRS, and di-methylation of Me-PPKRIA) by both 
enzymes.  
 










              We have characterized the kinetic mechanism of recombinant NTMT1 using a 
fluorescence assay and mass spectrometry. The results of studying the initial velocity 
indicate that methylation by NTMT1 proceeds via a random sequential bi-bi mechanism, 
which implicates that both SAM and peptide substrate need to bind to NTMT1 to form a 
ternary complex to initiate enzymatic reaction. This mechanism supports our rationales 
of designing bisubstrate inhibitors that mimic the ternary complex during enzyme 
catalysis. Thus compound could simultaneously inhibit both binding sites. In addition, 
our processivity studies demonstrate that NTMT1 proceeds via a distributive 
mechanism for multiple methylations. Our processivity studies had indicated the 
existence of mono- and di-methylated substrates of significant concentrations while 
enzyme catalysis reactions, which indirectly suggests that both mono- and di-
methylated substrate play roles in the biological system. 
              The results of peptides’ length, methylation states, and sequence on substrate 
recognition showed that hexapeptides gave comparable Km and kcat values. The Km 
studies for peptides with varied N-terminal residues defined that NTMT1 can recognize 
a motif X-P-K/R, where X can be any amino acid except D/E. Newly identified substrates 
like centromere H3 variants (CENP-A/B) supported this expanded consensus. We also 
determined that conserved residues N168, W136, D117, and D188 are critical for 





had provided valuable information in terms of substrate binding and recognition in 
structural basis, which lay a solid foundation for designing of highly selective 
peptidomimetic and/or small molecule inhibitors in the future.   
              In the meantime, we utilized computational studies and fluorescence assays to 
discover a small molecule inhibitor that targets the substrate binding site of NTMT1.  We 
identified one compound that exhibits potent inhibitory activity with an IC50 value of 7.4 + 
0.6 µM. Moreover, this compound showed selectivity for NTMT1 compared with PRMT1 
and G9a. Even through the molecular structure of this compound remains to be 
validated, however it is the first non-substrate analogue inhibitor identified so far for 
NTMT1. It can be used as a lead for inhibitor design. 
              Lastly, our results suggest that NTMT2 is able to di- and tri-methylate those 
substrate peptides that have high binding affinity to NTMT1/2, such as GPKRRQ, 
GPRRRS, and PPKRIA (MePPKRIA). However, most peptides that can be di-
methylated by NTMT1 were not being able to di-methylated by NTMT2. Our studies 
confirmed that NTMT2 can monomethylate all NTMT1 substrates. Furthermore, we 
discovered that it is capable of di-, tri-methylate some substrates with high binding 








4. Future direction 
              Even though the N-terminal methylation modification has been known for a 
long time, it began to stimulate increasing interest after the discovery of NTMT1 in 2010. 
Studies about this modification and its enzymes are still at very early stage. In our study, 
we have demonstrated that NTMT1 is adopting Bi-Bi mechanism while catalysis 
reaction and its substrates are methylated in a distributive fashion. Our structural basis 
study indicated a few important residues in substrate binding site and refined its 
substrate motif to X-P-K/R, where X can be any amino acid except D/E. However, there 
remains little explanation for the high binding affinity of peptides with X = Pro (PPKRIA), 
which is derived from mouse RCC1. Also the catalytic mechanism of NTMT1 still needs 
to be further elucidated. Structural characterization of our identified small molecule 
inhibitor remains to be clarified.  
              Compared to NTMT1, NTMT2 is a newly identified N-methyltransferse. It was 
reported as a monomethylase that plays a role to prime the substrates of NTMT1 to 
facilitate further methylation of substrates by NTMT1. However, our methylation 
progression assay indicates that NTMT2 is capable of di- and tri-methylation of some 
peptides that have high binding affinity to NTMT2. Future studies are needed to 
understand whether this is due to substrate specificity or the methylation rate difference 





              Protein α-N-terminal methylation plays an important role in regulating protein-
DNA interactions, mitotic division and DNA damage repair; however, little is known 
about the biological functions of this modification. Therefore, identification of proteins 
that recognize and bind to N-terminal methylated proteins would advance our 

















5. Experimental and methods 
5.1 Materials and instruments 
              SAM, ThioGlo1, Tris, KCl, NaCl, TECP, NH4H2PO4, TFA, dimethylformamide, 
α-Cyano-3-hydroxycinnamic acid, amino acids, and other chemicals and reagents were 
purchased from VWR, Fischer, Aldrich, EMD, Caliochem and Chemlmpex. NTMT1 (AD-
003) clone was purchased from Addgene. SAHH clone was obtained from Dr. Raymond 
C. Trievel through a Materials Transfer Agreement. 
              Flexstation3 Multi-Mode Microplate Reader was utilized for NTMT1 kinetic 
characterization. And methylation progression assay was carried out via an Applied 
Biosystems Voyager matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometer. 
 
5.2 NTMT1 purification 
NTMT1 preparation for kinetic studies 
              His-NTMT1 was expressed in E. coli BL21 (DE3) codon plus RIL cells in 
Terrific Broth medium in the presence of 50 g/mL kanamycin, using a pET28a-LIC 
expression vector that encodes a full-length NTMT1 (aminoacids1–222) with His6 tag 





β-D-1-thiogalactopyranoside (final concentration 1 mM), and incubated overnight at 
15 °C. Cells were harvested by centrifugation at 5,000 rpm. Cell pellets were suspended 
in the lysis buffer containing 25 mM Tris-HCl buffer (pH 8.0) containing 300 mM NaCl 
and 10 mM imidazole, lysed by passing through a Microfluidizer (MicrofluidicsCorp.) at 
20,000 p.s.i., and centrifuged at 15,000 rpm for 15 min at 4 °C. The supernatant was 
loaded on to a nickel-nitrilotriacetic acid agarose column. After removal of unbound 
protein by extensive washing with the lysis buffer, the protein was eluted with 25 mM 
Tris-HCl buffer (pH 8.0) containing 100 mM imidazole and 300 mM NaCl.  Combined 
elution fractions were dialyzed in the dialysis buffer (25 mM Tris, pH7.5, 150 mM NaCl, 
50 mM KCl) three times to provide His-NTMT1. The yield was 20 mg/L.  
 
NTMT1 preparation for crystal structure and mutagenesis 
              The gene of human NTMT1 (2-223) was amplified and cloned into a modified 
pET28a-LIC vector to express NTMT1 with a 6 His-tag and a thrombin cleavage site at 
the N-terminus. The recombinant NTMT1 plasmid was transformed into E. coli BL21 
(DE3) codon plus RIL strain for induced expression with 0.2 mM IPTG at 16 °C 
overnight. NTMT1 was purified by Ni2+-affinity and anion-exchange chromatography, 
followed by further purification through Superdex™ 200 10/300 (GE Healthcare). The 
buffer for gel filtration contained 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM TECP. 
The peak fractions were collected and concentrated to 37 mg/mL for crystallization 






5.3 Peptide preparation 
              hRCC1-6 (SPKRIA, [M+H]+ = 670.4359), hRCC1-9 (SPKRIAKRR, [M+H]+ = 
1110.7331), hRCC1-10 (SPKRIAKRRS, [M+H]+ = 1197.7651), and hRCC1-12 
(SPKRIAKRRSPP, [M+H]+ = 1392.8546) were synthesized on Rink amide resin using 
standard Fmoc chemistry with a CEM Liberty microwave peptide synthesizer. Fmoc 
protection groups at the α-N-termini were removed by 20% (v/v) piperidine in N,N-
dimethylformamide. MeRCC1-10 was synthesized based on literature.103 The Me2-
RCC1-10 peptide was synthesized as follows. To the deprotected RCC1-10 peptide on 
resin (0.1 mmol) in N,N-dimethylformamide (2 mL) was added formaldehyde (24 µL of 
37% (w/v) solution, 0.24 mmol), HOAc (20 µL), and NaBH3CN (15 mg, 0.24 mmol). The 
mixture was placed on a shaker for 4 h. The resin was washed with N,N-
dimethylformamide, and the reaction was repeated. 
 
5.4 Fluorescence intensity vs. [GSH] correlation study 
              A three-fold serial dilution of GSH (0~30 μM) with 1x buffer solution (25 mM 
Tris-HCl, pH 7.5, 50 mM KCl) was conducted.  The reaction was initiated by addition of 
10 μL of GSH solution in different concentration to each well of 96-well microplate 
containing 10 μL of 10x reaction buffer (250 mM Tris-HCl, pH 7.5, 500 mM KCl),  1 μL 
ThioGlo1 (1.5 mM stock solution in DMSO) and 79 μL ddH2O.  Subsequently, 96-well 
microplate with testing sample was placed into FlexStation 3 microplate reader preset at 
37 °C. The program was set as: kinetics, fluorescence bottom read, excitation of 370 





After the fluorescence intensity was measured, the obtained raw data was processed to 
make a plot of Relative Fluorescence Units (RFU) as a function of GSH concentrations 
in Microsoft Office Excel scatter plot. The value for R2 was calculated after linear 
regression. 
 
5.5 Time-dependent studies 
              A reaction mixture of 0.2 μM NTMT1, 10 μM SAHH, 100 μM SAM, and 15 μM 
ThioGlo1 in buffer (25 mM Tris, 50 mM KCl, pH = 7.5) was premixed (90 µL in total) and 
transferred to a well of 96-well microplate. The reaction was initiated with 10 μL of 50 
μM RCC1-10, and incubated in the FlexStation 3 at 37 °C for 5 min. The program of 
FlexStation 3 was set as: kinetics, fluorescence bottom read, excitation of 370 nm, 
emission of 500 nm, duration 15 min with measurements at 15 seconds intervals. And 
the reaction was monitored continuously for 15 min. The obtained RFU was converted 
to [SAH] using the standard curve obtained (RFU vs. [GSH]). Then, data was processed 
to make a plot of [SAH] as a function of time as a Microsoft Office Excel scatter plot. 
The value for R2 was calculated after linear regression. 
 
5.6 Concentration-dependent studies  
              A reaction mixture of 10 μM SAHH, 100 μM SAM, and 15 μM ThioGlo1 in 1x 
buffer solution (25 mM Tris-HCl, pH 7.5, 50 mM KCl) was premixed (89 µL in total) and 





different concentrations: 40 µM, 30 µM, 20 µM, 10 µM, 5 µM. 1 µL of NTMT1 solution at 
varied concentration was added into the above reaction mixture. The reaction was next 
initiated with 10 μL of 50 μM of RCC1-10, incubated under 37 °C for 5 min, and 
monitored by the FlexStation3 microplate reader (kinetics, fluorescence bottom read, 
excitation of 370 nm, emission of 500 nm, duration 15 min with measurements at 15 
seconds intervals). The obtained RFU was converted to [SAH] using the standard curve 
obtained (RFU vs. [GSH]). Then, data was processed to make a plot of [SAH] as a 
function of time in Microsoft Office Excel scatter plot. Initial rates were calculated and 
processed to make a plot of rate as a function of [NTMT1]. Then, data was processed to 
make a plot of [SAH] as a function of time as a Microsoft Office Excel scatter plot.  
 
5.7 Steady state kinetic characterization of NTMT1 substrates  
5.7.1 SAM  
Serial dilution of SAM was carried out to a final concentration range (100 µM, 50 µM, 25 
µM, 12.5 µM, 6.3 µM, 3.1 µM, 1.6 µM). A reaction mixture of 0.2 μM NTMT1, 10 μM 
SAHH, SAM, and 15 μM ThioGlo1 was premixed in the 1x reaction buffer (25 mM Tris, 
50 mM KCl, pH  7.5) and 90 µL was transferred to each well of 96-well microplate and 
incubated at 37 °C for 5 min. The reaction was next initiated with 10 μL of 50 μM of 
RCC1-12, incubated under 37 °C for 5 min, and monitored by the FlexStation3 
microplate reader (kinetics, fluorescence bottom read, excitation of 370 nm, emission of 
500 nm, duration 15 min with measurements at 15 seconds intervals). The obtained 





model using least square nonlinear regression regression with GraphPad Prism 5 
(Version 5.04). 
5.7.2 Peptide substrates 
              Each peptide was diluted to 10 mM using deionized water. Serial dilution was 
carried out to a final concentration range (64 µM, 32 µM, 16 µM, 8 µM, 4 µM, 2 µM, 1 
µM, 0.5 µM, 0). A test run was carried out following the fluorescence assay as 
described previously to estimate the concentration range for kinetics studies. Based on 
the results of these test runs, specific serial dilutions tailored for each peptide were 
adjusted.   
              A reaction mixture of 0.2 μM NTMT1, 10 μM SAHH, 100 μM SAM, and 15 μM 
ThioGlo1 was premixed in the 1x reaction buffer (25 mM Tris, 50 mM KCl, pH  7.5) and 
90 µL was transferred to each well of 96-well microplate and incubated at 37 °C for 5 
min. The reaction was next initiated with addition of varied concentrations of RCC1-12 
in different wells and monitored by the FlexStation3 microplate reader for 15 min. The 
result was processed by Microsoft Office Excel scatter plot. The obtained data were 
processed as described before and subsequently fit into Michaelis-Menten model using 
least square nonlinear regression regression with GraphPad Prism 5 (Version 5.04). 
 
5.8 NTMT1 kinetic mechanism characterization  
              RCC1-10 was prepared in varied concentrations (20 μM, 10 μM, 5 μM, 2.5 μM, 





experiments with varied SAM concentration (12.5 μM, 25 μM, 50 μM, 100 μM) were 
carried out in parallel. The detailed experimental procedures were as described above. 
Obtained initial velocities from each experiment were globally fitted into Lineweaver-
Burk kinetic equation using least square nonlinear regression GraphPad Prism 5 
software (Version 5.04).   
              For the SAM binding site, SAM was prepared in varied concentration (51.2 μM, 
25.6 μM, 12.8 μM, 6.4 μM, 3.2 μM, 1.6 μM) through serial dilution with deionized water. 
Different RCC1-10 concentrations (1 μM, 2 μM, 4 μM, 8 μM) were used for each 
experiment.  Similarly, the obtained initial velocity from each experiment was globally fit 
with the Lineweaver-Burk kinetic equation using least square nonlinear regression 
GraphPad Prism 5 software (Version 5.04). 
 
5.9 MALDI-MS methylation progression study 
NTMT1 methylation progression studies 
              The reaction buffer (20 mM Tris, 50 mM KCl, pH 7.5), RCC1-10 (10 μM), and 
NTMT1 (0.2 μM) were premixed, and incubated in a 30 °C water bath for 5 min. After 
incubation, the reaction was initiated by addition of 50 μM SAM. The reaction took 2 
hours. Every 20 min, a 3 μL sample was withdrawn from the reaction mixture, and 
quenched in 1:1 ratio using quenching solution (20 mM NH4H2PO4, 0.4% (v/v) TFA, in 
1:1 ACN/water). 1 μL quenched samples were spotted onto MALDI plate along with α-





Methylation progression studies of peptides of varied first residue with NTMT1 and 
NTMT2 
              A 36 µL reaction mixture was prepared, which is composed of: 2 µL NTMT1/2 
(40 µM), 30 µL reaction buffer (20 µM Tris, 50 µM NaCl, pH = 7.5), and 4 µL peptide 
substrate (200 µM). This reaction mixture was incubated in 30 °C water bath for 5 
minutes, and initiated with 4 µL SAM (400 µM). At each time point (0 min, 15 min, 30 
min, 60 min, 120 min, overnight), 3 µL of reaction mixture was withdrawn and quenched 
in 1:1 ratio by quenching solution (20 mM NH4H2PO4, 0.4% (v/v) TFA, in 1:1 ACN/water). 
Quenched samples were spotted onto MALDI plate along with α-cyano-3-
hydroxycinnamic acid, and examined by MALDI-MS. 
MALDI-MS based study of endogenous SAM 
              Buffer (20 mM Tris-HCl, 150 mM NaCl, pH 7.5) was mixed with 50 μM SAM 
and 1 mM peptide (SPKRIA, PPKRIA, RPKRIA, YPKRIA). Reaction mixtures were 
incubated at 30 °C for 2 h. After 2 h, the testing samples were withdrawn from each 
reaction mixtures were subsequently quenched in 1:1 ratio by the quenching solution 
(20 mM NH4H2PO4, 0.4% (v/v) TFA, in 1:1 ACN/water). These quenched samples were 









5.10 Virtual screening and docking studies 
               By using the NTMT1 – SAH binary complex (PDB ID: 2EX4, 1.75Å) crystal 
structure model, a query was designed based on the predicted interactions between 
substrate and NTMT1. An aromatic region was defined complementary to Trp137. And 
a hydrophobic region was defined in the center of Val218, Leu211, and Ile37. The acid 
side chain of Asp181 was defined as an acceptor atom. Finally, a negative center was 
defined (surrounded by Asp181, Asp178, Asp168, and Ser163). Subsequently, a virtual 
screening was carried out by using designed query. Libraries used for virtual screening 
include NCI, Asinex, Chembridge, Maybridge, Otava, and SigmaAldric. In total, there 
were around 2,500,000 compounds were surveyed. 
               Hits obtained from virtual screening were docked into both binding sites of 
NTMT1. Results were shown as scores using HINT (Hydropathic INTeractions) score 
functions. Both SAM and peptide binding sites were scored. Docking scores of SAM 
binding site was used as a reference to compare with those of the peptide binding site. 
Molecules with high scores at the peptide binding site, and low scores at the SAM 
binding site were expected. This observation suggests that such hits have higher 









5.11 Biochemical screening of small molecule compounds 
5.11.1 Primary screening using SAHH-coupled fluorescence assay 
               The samples to be tested were diluted and prepared as 10 mM stock solutions 
in 1.5 mL amber vials. 1 μL (10 mM) of each sample was added into each well of 
microplate. Subsequently, 90 μL of reaction mixture was prepare for each well of a 96-
well microplate. The reaction mixture is composed of 0.2 μM NTMT1, reaction buffer (20 
mM Tris, 50 mM KCl, pH 7.5), 10 μM SAHH, 100 μM SAM (10 x Km concentration) and 
15 μM  ThioGlo1. Reactions were initiated with 10 μL (50 μM) (1 x Km concentration) of 
RCC1-10, and measured by the FlexStation3 microplate reader. The obtained raw data 
were processed by Microsoft Office Excel in scatter plots.  
 
5.11.2 Secondary screening to remove false positive  
              Four parallel inhibition assays of each candidate were carried out, preparation 
procedure and methodology were as described previously. The first and second 
experiments have varied SAHH concentrations, 1 x SAHH and 2 x SAHH respectively. 
And the third and fourth experiments have 0.01% and 0.04% of triton. The obtained 
data were processed by Microsoft Office Excel in scatter plots.  
5.11.3 IC50 studies 
              Three-fold serial dilution of each sample was carried out with DMSO, and 1 μL 
of each sample in different concentrations were added into a 96-well microplate. 





with 10 uL (50 μM) RCC1-10, incubated under 37 °C, and read by FlexStation3 
microplate reader. The obtained data was firstly processed by Microsoft Office Excel in 
scatter plots; and IC50 profiles were determined through SigmaPlot 5 using “response vs. 
Log conc.” of non-linear regression. 
 
5.11.4 Selectivity studies 
              IC50 studies were conducted as described previously with NTMT1, PRMT5, and 
G9a, respectively. Obtained data were processed by Microsoft Office Excel in scatter 
plots, and the IC50 profiles were determined through SigmaPlot 5 “response vs. Log 
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Table 1. Molecular mass of peptides of varied methylation states 
  
Mass SPKRIA PPKRIA YPKRIA RPKRIA DPKRIA
M+H 671 681 747 740 699
M+Na 693 703 769 762 721
M+K 709 719 785 778 737
M+Me+H 685 695 761 754 713
M+Me+Na 707 717 783 776 735
M+Me+K 723 733 799 792 751
M+2Me+H 699 709 775 768 727
M+2Me+Na 721 797 790 749
M+2Me+K 737 813 806 765
M+3Me 683 789 782 741
Mass WPKRIA QPKRIA GPKRRQ GPRRRS LPKRIA NPKRIA
M+H 770 712 740 727 697 698
M+Na 792 734 762 749 719 720
M+K 808 750 778 765 735 736
M+Me+H 784 726 754 741 711 712
M+Me+Na 806 748 776 763 733 734
M+Me+K 822 764 792 779 749 750
M+2Me+H 798 740 768 755 725 726
M+2Me+Na 820 762 790 777 747 748
M+2Me+K 836 778 806 793 763 764
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